{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T00:28:11Z","timestamp":1789604891385,"version":"build-2803163510"},"reference-count":41,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer\/Radioth\u00e9rapie"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1016\/j.canrad.2021.05.006","type":"journal-article","created":{"date-parts":[[2021,8,5]],"date-time":"2021-08-05T09:25:40Z","timestamp":1628155540000},"page":"433-439","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Volumetric modulated arctherapy for locally advanced nasopharyngeal carcinoma: Clinical efficacy and late toxicity"],"prefix":"10.1016","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8736-2263","authenticated-orcid":false,"given":"M.","family":"Hommadi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"N\u2019da","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Bertrand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Randriamaroson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Benlemlih","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.B.A.","family":"Mosse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"El Mejjaoui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Kebdani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"El Kacemi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Benjaafar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.canrad.2021.05.006_bib0210","first-page":"394","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.canrad.2021.05.006_bib0215","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1200\/JCO.1998.16.4.1310","article-title":"Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099","volume":"16","author":"Al-Sarraf","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2021.05.006_bib0220","doi-asserted-by":"crossref","first-page":"6730","DOI":"10.1200\/JCO.2005.16.790","article-title":"Randomized trial of radiotherapy vs concurrent chemoradiotherapy followed by adjuvant chemotherapy in patients with American joint committee on cancer\/international union against cancer stage III and IV nasopharyngeal cancer of the endemic variety","volume":"23","author":"Wee","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2021.05.006_bib0225","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.ijrobp.2005.06.037","article-title":"Chemotherapy in locally advanced nasopharyngeal carcinoma: an individual patient data meta-analysis of eight randomized trials and 1753 patients","volume":"64","author":"Baujat","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2021.05.006_bib0230","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S1470-2045(11)70320-5","article-title":"Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial","volume":"13","author":"Chen","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.canrad.2021.05.006_bib0235","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1016\/S1470-2045(16)30410-7","article-title":"Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase 3, multicentre, randomised","volume":"17","author":"Sun","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.canrad.2021.05.006_bib0240","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1002\/ijc.32099","article-title":"Concurrent chemoradiotherapy with\/without induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma: long-term results of phase 3 randomized controlled trial","volume":"145","author":"Li","year":"2019","journal-title":"Int J Cancer"},{"key":"10.1016\/j.canrad.2021.05.006_bib0245","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/S0360-3016(03)00075-0","article-title":"Intensity-modulated radiotherapy in nasopharyngeal carcinoma: dosimetric advantage over conventional plans and feasibility of dose escalation","volume":"56","author":"Kam","year":"2003","journal-title":"Int J Radiat Biol Oncol Phys"},{"key":"10.1016\/j.canrad.2021.05.006_bib0250","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1080\/02841860600635862","article-title":"Nasopharyngeal carcinoma. Treatment planning with IMRT and 3D conformal radiotherapy","volume":"46","author":"Kristensen","year":"2007","journal-title":"Acta Oncol"},{"key":"10.1016\/j.canrad.2021.05.006_bib0255","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ijrobp.2005.03.057","article-title":"Intensity-modulated radiation therapy (IMRT) for nasopharynx cancer: update of the memorial Sloan-Kettering experience","volume":"64","author":"Wolden","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2021.05.006_bib0260","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1016\/j.ijrobp.2004.05.022","article-title":"Treatment of nasopharyngeal carcinoma with intensity-modulated radiotherapy: the Hong Kong experience","volume":"60","author":"Kam","year":"2004","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2021.05.006_bib0265","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1056\/NEJMoa1905287","article-title":"Gemcitabine and cisplatin induction chemotherapy in nasopharyngeal carcinoma","volume":"381","author":"Zhang","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.canrad.2021.05.006_bib0270","doi-asserted-by":"crossref","unstructured":"Nasopharyngeal cancer TNM staging AJCC UICC, 8th edn; 2018.","DOI":"10.18632\/oncotarget.18158"},{"key":"10.1016\/j.canrad.2021.05.006_bib0275","unstructured":"International guideline for the delineation of the clinical target volumes (CTV) for nasopharyngeal carcinoma."},{"key":"10.1016\/j.canrad.2021.05.006_bib0280","unstructured":"International Consensus Guidelines for the CT-based delineation of neck levels."},{"key":"10.1016\/j.canrad.2021.05.006_bib0285","unstructured":"International guideline on dose prioritization and acceptance criteria in radiation therapy planning for nasopharyngeal carcinoma."},{"key":"10.1016\/j.canrad.2021.05.006_bib0290","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1002\/ijc.25516","article-title":"Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008","volume":"127","author":"Ferlay","year":"2010","journal-title":"Int J Cancer"},{"key":"10.1016\/j.canrad.2021.05.006_bib0295","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1016\/S0140-6736(15)00055-0","article-title":"Nasopharyngeal carcinoma","volume":"387","author":"Chua","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.canrad.2021.05.006_bib0300","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.radonc.2012.08.013","article-title":"A prospective, randomized study comparing outcomes and toxicities of intensity-modulated radiotherapy vs. conventional two-dimensional radiotherapy for the treatment of nasopharyngeal carcinoma","volume":"104","author":"Peng","year":"2012","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.canrad.2021.05.006_bib0305","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/j.ijrobp.2006.06.013","article-title":"Xerostomia and quality of life after intensity-modulated radiotherapy vs. conventional radiotherapy for early-stage nasopharyngeal carcinoma: initial report on a randomized controlled clinical trial","volume":"66","author":"Pow","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2021.05.006_bib0310","doi-asserted-by":"crossref","first-page":"4873","DOI":"10.1200\/JCO.2007.11.5501","article-title":"Prospective randomized study of intensity-modulated radiotherapy on salivary gland function in early-stage nasopharyngeal carcinoma patients","volume":"25","author":"Kam","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2021.05.006_bib0315","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/S1470-2045(15)70126-9","article-title":"MAC-NPC Collaborative Group, Chemotherapy and radiotherapy in nasopharyngeal carcinoma: an update of the MAC-NPC meta-analysis","volume":"16","author":"Blanchard","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.canrad.2021.05.006_bib0320","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S1470-2045(11)70320-5","article-title":"Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial","volume":"13","author":"Chen","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.canrad.2021.05.006_bib0325","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.ejca.2017.01.002","article-title":"Adjuvant chemotherapy in patients with locoregionally advanced nasopharyngeal carcinoma: long-term results of a phase 3 multicentre randomised controlled trial","volume":"75","author":"Chen","year":"2017","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.canrad.2021.05.006_bib0330","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1016\/S1470-2045(16)30410-7","article-title":"Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase 3, multicentre, randomised controlled trial","volume":"17","author":"Sun","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.canrad.2021.05.006_bib0335","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.ejca.2019.07.007","article-title":"Induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: long-term results of a phase III multicentre randomised controlled trial","volume":"119","author":"Yang","year":"2019","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.canrad.2021.05.006_bib0340","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.radonc.2015.11.030","article-title":"Comparison of weekly versus triweekly cisplatin delivered concurrently with radiation therapy in patients with locally advanced nasopharyngeal cancer: A multicenter randomized phase II trial (KCSG-HN10-02)","volume":"118","author":"Lee","year":"2016","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.canrad.2021.05.006_bib0345","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1093\/jnci\/djr432","article-title":"Concurrent chemoradiotherapy vs radiotherapy alone in stage II nasopharyngeal carcinoma: phase III randomized trial","volume":"103","author":"Chen","year":"2011","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.canrad.2021.05.006_bib0350","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.ejca.2010.10.026","article-title":"Factors contributing to the efficacy of concurrent-adjuvant chemotherapy for locoregionally advanced nasopharyngeal carcinoma: combined analyses of NPC-9901 and NPC-9902 Trials","volume":"47","author":"Lee","year":"2011","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.canrad.2021.05.006_bib0355","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.radonc.2011.12.022","article-title":"Prognostic significance of the total dose of cisplatin administered during concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma","volume":"104","author":"Loong","year":"2012","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.canrad.2021.05.006_bib0360","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.radonc.2013.10.020","article-title":"Long-term outcomes of intensity-modulated radiotherapy for 868 patients with nasopharyngeal carcinoma: an analysis of survival and treatment toxicities","volume":"110","author":"Sun","year":"2014","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.canrad.2021.05.006_bib0365","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0167-8140(97)01914-2","article-title":"Carcinoma of the nasopharynx treated by radiotherapy alone: determinants of distant metastasis and survival","volume":"43","author":"Geara","year":"1997","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.canrad.2021.05.006_bib0370","doi-asserted-by":"crossref","first-page":"5700","DOI":"10.1158\/1078-0432.CCR-05-0648","article-title":"A comparison study of different PCR assays in measuring circulating plasma epstein-barr virus DNA levels in patients with nasopharyngeal carcinoma","volume":"11","author":"Le","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.canrad.2021.05.006_bib0375","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1056\/NEJMoa032260","article-title":"Quantification of plasma Epstein-Barr virus DNA in patients with advanced nasopharyngeal carcinoma","volume":"350","author":"Lin","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.canrad.2021.05.006_bib0380","doi-asserted-by":"crossref","first-page":"5414","DOI":"10.1200\/JCO.2006.07.7982","article-title":"Plasma Epstein-Barr viral deoxyribonucleic acid quantitation complements tumor-node-metastasis staging prognostication in nasopharyngeal carcinoma","volume":"24","author":"Leung","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2021.05.006_bib0385","doi-asserted-by":"crossref","first-page":"3337","DOI":"10.1002\/cncr.26550","article-title":"Randomized controlled trial of acupuncture for prevention of radiation-induced xerostomia among patients with nasopharyngeal carcinoma","volume":"118","author":"Meng","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.canrad.2021.05.006_bib0390","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1016\/S0360-3016(00)00786-0","article-title":"Final report of a randomized trial on altered-fractionated radiotherapy in nasopharyngeal carcinoma prematurely terminated by significant increase in neurologic complications","volume":"48","author":"Teo","year":"2000","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2021.05.006_bib0395","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/S0194-5998(01)73640-6","article-title":"Internal carotid artery hemorrhage after irradiation and osteoradionecrosis of the skull base","volume":"125","author":"Lam","year":"2001","journal-title":"Otolaryngol Head Neck Surg"},{"key":"10.1016\/j.canrad.2021.05.006_bib0400","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1017\/S0022215100143622","article-title":"Temporal bone tumours in patients irradiated for nasopharyngeal neoplasm","volume":"113","author":"Goh","year":"1999","journal-title":"J Laryngol Otol"},{"key":"10.1016\/j.canrad.2021.05.006_bib0405","series-title":"World Health Organization Classification of Tumours","article-title":"Pathology and genetics of head and neck tumors","year":"2005"},{"key":"10.1016\/j.canrad.2021.05.006_bib0410","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.oraloncology.2017.12.004","article-title":"Treatment outcomes of nasopharyngeal carcinoma in modern era after intensity modulated radiotherapy (IMRT) in Hong Kong: a report of 3328 patients (HKNPCSG 1301 study)","volume":"77","author":"Au","year":"2018","journal-title":"Oral Oncol"}],"container-title":["Cancer\/Radioth\u00e9rapie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1278321821001049?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1278321821001049?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T12:34:55Z","timestamp":1761136495000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1278321821001049"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":41,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["S1278321821001049"],"URL":"https:\/\/doi.org\/10.1016\/j.canrad.2021.05.006","relation":{},"ISSN":["1278-3218"],"issn-type":[{"value":"1278-3218","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Volumetric modulated arctherapy for locally advanced nasopharyngeal carcinoma: Clinical efficacy and late toxicity","name":"articletitle","label":"Article Title"},{"value":"Cancer\/Radioth\u00e9rapie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canrad.2021.05.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Soci\u00e9t\u00e9 fran\u00e7aise de radioth\u00e9rapie oncologique (SFRO). Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}